West Pharmaceutical Services, I

Valuation Analysis

About the Company

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment a

West Pharmaceutical Services, I Stock at a Glance

West Pharmaceutical Services, I (WST) is currently trading at $328.82 with a market capitalization of $23.2B. The trailing P/E ratio stands at 44.08x, with a forward P/E of 34.41x. The 52-week range spans from $206.80 to $336.82; the current price is 2.4% below the yearly high. Year-over-year revenue growth stands at +21.0%. The net profit margin stands at 16.85%.

💰 Dividend

West Pharmaceutical Services, I pays an annual dividend of $0.88 per share, representing a yield of 0.27%. The payout ratio stands at 11.5%.

📊 Analyst Rating

14 analysts rate West Pharmaceutical Services, I (WST) on consensus: Strong Buy. The average price target is $358.79, implying +9.11% from the current price. Analyst price targets range from $310.00 to $400.00.

West Pharmaceutical Services, I: The Investment Case in Detail

West Pharmaceutical Services, I (WST) operates in the Healthcare — specifically Medical Instruments & Supplies — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Revenue is growing at a healthy 21% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Earnings growth of 56.1% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. Free cash flow is positive and net margins stand at 16.85%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.

The Bear Case

Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valuation in Context

At a PEG of 3.16, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here. The EV/EBITDA multiple of 26.47x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

What to Watch Next

• The forward P/E of 34.41x is meaningfully below the trailing 44.08x — analysts expect earnings to step up; the next earnings release is the test.
• The share is trading at 93.8% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Risk Profile

The data points to market-like volatility.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy West Pharmaceutical Services, I?

Compare top-rated brokers — low fees, trusted providers, fully regulated.